Abstract: The present disclosure provides recombinant phages, a Wip1 p23 receptor binding protein and a Wip1 p24 receptor binding protein that bind to Bacillus anthracis. The disclosure further provides methods and uses thereof.
Type:
Application
Filed:
July 15, 2014
Publication date:
January 21, 2016
Applicant:
THE ROCKEFELLER UNIVERSITY
Inventors:
Vincent Fischetti, Raymond Schuch, Sherry Kan
Abstract: An ion transfer device for transferring ions emerging from an electrospray ion source at atmosphere to a vacuum chamber includes an inner surface in the shape of a diverging conical duct. The ion transfer device has an entrance aperture for positioning proximate the exit port of the electrospray ion source emitter, the entrance aperture receiving the electrosprayed ions from the exit port of the electrospray ion source emitter at atmosphere, the diverging conical duct being an electrode toward which the ions migrate and having an exit aperture with an inner diameter larger than an inner diameter of its entrance aperture, the exit aperture enclosed in the vacuum chamber, the diverging conical duct transporting the ions from atmosphere to vacuum. The vacuum chamber can be a chamber of a vacuum housing enclosing a mass analyzer.
Type:
Grant
Filed:
April 28, 2015
Date of Patent:
January 19, 2016
Assignee:
THE ROCKEFELLER UNIVERSITY
Inventors:
Andrew N. Krutchinsky, Julio Padovan, Herbert Cohen, Brian T. Chait
Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
Abstract: Pro-apoptotic compounds having a tripartite structure: A-L-B are disclosed. In these compounds A is an IBM mimetic moiety; L is a linker and B is a moiety that binds to a protein on the outer mitochondrial membrane. The compounds are useful for inducing cell apoptosis and therefore treating cancer.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
December 15, 2015
Assignee:
The Rockefeller University
Inventors:
Hermann Steller, Cristinel Sandu, Anshuman Kelkar, Nidhi Gangadhar
Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ ID NOs: 1-94; 281-374; 467-481; 497-522; or 549, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary. The invention further relates to modified single stranded microRNA molecules, isolated single stranded anti-microRNA molecules and isolated microRNP molecules. In another embodiment, the invention relates to a method for inhibiting microRNP activity in a cell.
Abstract: The present invention relates to the phosphohistidine analogs of the present invention which of the formula and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine.
Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.
Type:
Grant
Filed:
March 10, 2014
Date of Patent:
December 1, 2015
Assignee:
The Rockefeller University
Inventors:
Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention relates to transcriptional gene silencing (TGS) of endogenes in plants, plant tissue and plant cells. More specifically, the present invention relates to nucleic acid constructs that are capable of more effectively silencing genes of interest, such as endogenes, in plants, plant tissue and plant cells by TGS. The present invention further relates to methods of more effectively reducing endogenous gene expression in plants, plant tissues or plant cells by TGS using the nucleic acid constructs of the invention.
Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.
Abstract: The invention provides a novel truncated mutated T4 RNA ligase 2. In addition, methods are provided for ligating pre-adenlylated donor molecules to the 3? hydroxyl group of RNA in the absence of ATP using the ligase.
Type:
Grant
Filed:
July 8, 2014
Date of Patent:
October 27, 2015
Assignee:
The Rockefeller University
Inventors:
Thomas Tuschl, Janos Ludwig, Yi Pei, Carolina Lin
Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
Abstract: The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.
Type:
Grant
Filed:
November 22, 2010
Date of Patent:
October 13, 2015
Assignees:
THE ROCKEFELLER UNIVERSITY, THE CHILDREN'S HOSPITAL MEDICAL CENTER
Inventors:
Paul Greengard, David Repaske, Gretchen Snyder
Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
Type:
Application
Filed:
October 18, 2013
Publication date:
October 1, 2015
Applicants:
THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventors:
Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
Abstract: Compounds of formula (I) in which R3 is chosen from hydrogen, cyano, nitro, acetyl and C(?O)NH2, and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl, are useful as antitumor agents.
Type:
Grant
Filed:
January 18, 2012
Date of Patent:
September 29, 2015
Assignee:
The Rockefeller University
Inventors:
James K. Chen, Tarun M. Kapoor, Ari J. Firestone, Joshua S. Weinger
Abstract: Methods for identifying compounds that modulate the ion channel activity of a Kir channel are provided. Methods for identifying compounds that selectively modulate the ion channel activity of specific types of Kir channels based on the turret region of a Kir channel are also provided. Methods for identifying compounds to treat conditions associated with abnormal ion channel activity are also provided. Compounds including purified antibodies and methods of making antibodies which bind to the turret region of a Kir channel are provided. Purified polypeptides including at least a portion of the turret region of a Kir channel and nucleic acid sequences encoding these polypeptides are also provided.
Abstract: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc?RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.
Abstract: The present invention relates to transcriptional gene silencing (TGS) of endogenes in plants, plant tissue and plant cells. More specifically, the present invention relates to nucleic acid constructs that are capable of TGS of endogenes in plants, plant tissue and plant cells. The present invention further relates to methods of reducing endogenous gene expression in plants, plant tissues or plant cells by TGS using the nucleic acid constructs of the invention.
Abstract: An ion trap includes a containment region for containing ions, and a plurality of electrodes positioned on a regular polyhedral structure encompassing the containment region. An electrode is positioned on each vertex of the encompassing structure and at least one of the polygonal surfaces includes additional electrodes configured to form a plurality of quadrupoles on the surface. Alternating RF voltage is applied to the plurality of electrodes, so that directly neighboring electrodes are of equal amplitude and opposite polarity at any point in time. This configuration on the polyhedral structure forms a potential barrier for repelling the ions from each of the regular polygonal surfaces and containing them in the trap. Mass selective filters can be formed from the quadrupoles for parallel mass analysis in different m/z windows. Application of a small DC potential to a plate electrode outside the quadrupoles preferentially depletes single charged ions for enhanced signal-to-noise analysis.
Type:
Grant
Filed:
September 23, 2014
Date of Patent:
September 8, 2015
Assignee:
THE ROCKEFELLER UNIVERSITY
Inventors:
Andrew N. Krutchinsky, Vadim Sherman, Herbert Cohen, Brian T. Chait
Abstract: A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo.